RiteMED Escitalopram

RiteMED Escitalopram

escitalopram

Manufacturer:

RiteMED

Distributor:

RiteMED
Concise Prescribing Info
Contents
Escitalopram oxalate
Indications/Uses
Major depressive episodes, panic disorder w/ or w/o agoraphobia, social anxiety disorder (social phobia), generalized anxiety disorder, obsessive-compulsive disorder.
Dosage/Direction for Use
Major depressive episodes 10 mg once daily for 2-4 wk may be increased to max of 20 mg/day. Panic disorder w/ or w/o agoraphobia Initially 5 mg for the 1st wk before increasing to 10 mg daily may be increased up to max of 20 mg/day. Social anxiety disorder 10 mg once daily for 2-4 wk. May be decreased to 5 mg or increased to a max of 20 mg daily. Generalised anxiety disorder Initially 10 mg once daily. Max: 20 mg daily. Obsessive-compulsive disorder Initially 10 mg once daily. Max: 20 mg daily. Mild or moderate hepatic function Initially 5 mg daily for the 1st 2 wk. Patients known to be poor metabolisers of CYP2C19 Initially 5 mg daily during the 1st 2 wk. May be increased to 10 mg daily. Elderly >65 yr Initially 50 mg once daily.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. Concomitant use w/ non-selective, irreversible MAOIs, reversible MAO-A inhibitors (eg, moclobemide) or reversible non-selective MAOI linezolid & drugs known to prolong QT-interval. Patient w/ QT-interval prolongation or congenital long QT syndrome.
Special Precautions
Increased anxiety symptoms in patients w/ panic disorder at the beginning of treatment. Discontinue if patient develops seizures for the 1st time or if there is an increase in seizure frequency. Avoid in patients w/ unstable epilepsy. History of mania/hypomania. May alter glycemic control. Suicide/suicidal thoughts or clinical worsening. Depression. Akathisia/psychomotor restlessness. Patients w/ cirrhosis or use in combination w/ medications that may cause hyponatremia. Concomitant use w/ oral anticoagulants, medicinal products known to affect platelet function (eg, atypical antipsychotics & phenothiazines, TCAs, acetylsalicylic acid & NSAIDs, ticlopidine & dypiridamole, medicinal products w/ serotonergic effects eg, sumatriptan or other triptans, tramadol & tryptophan, St John's wort. Patients w/ known bleeding tendencies, coronary heart disease, significant bradycardia, recent acute MI or uncompensated heart failure. Electroconvulsive therapy. Abrupt w/drawal. Electrolyte disturbances eg, hypokalemia & hypomagnesemia. W/draw treatment if signs of cardiac arrhythmia occur. Monitor for clinical worsening, suicidal behavior or thoughts & unusual changes in behavior. Pregnancy & lactation. Elderly. Suicide-related behaviors & hostility in childn & adolescent <18 yr.
Adverse Reactions
Nausea. Decreased/increased appetite, increased wt; anxiety, restlessness, abnormal dreams; insomnia, somnolence, dizziness, paraesthesia, tremor; sinusitis, yawning; diarrhea, constipation, vomiting, dry mouth; increased sweating; arthralgia, myalgia tissue disorders; ejaculation disorder, impotence (men).
Drug Interactions
Risk of serotonin syndrome w/ irreversible MAOI, reversible MAO-A inhibitor eg, moclobemide, selegiline & serotonergic medicinal products (eg, tramadol, sumatriptan & other triptans). Non-selective, irreversible MAOIs. Reversible non-selective MAOI eg, linezolid. Medicinal products that prolong QT interval eg, class IA & III antiarrhythmics, antipsychotics (eg, phenothiazine derivatives, pimozide, haloperidol), TCAs, certain antimicrobial agents (eg, sparfloxacin, moxifloxacin, erythromycin IV, pentamidine, anti-malarial treatment particularly halofantrine), certain anti-histamines (astemizole, mizolastine). Moderate increase in plasma conc w/ cimetidine. Medicinal products that lower seizure threshold (eg, antidepressants, neuroleptics eg, phenothiazines, thioxanthenes & butyrophenones, mefloquine, bupropion & tramadol). Enhanced effects w/ lithium, tryptophan. Increased incidence of adverse reactions w/ St. John's wort. Altered anti-coagulant effects w/ oral anti-coagulants. May increase bleeding tendency w/ NSAIDs. Moderate increase in plasma conc w/ omeprazole. CYP2C19 inhibitors. Flecainide, propafenone, & metoprolol, some CNS acting medicinal products, antidepressants eg, desipramine, clomipramine & nortriptyline or antipsychotics eg, risperidone, thioridazine & haloperidol. Increased plasma conc w/ desipramine or metoprolol.
MIMS Class
ATC Classification
N06AB10 - escitalopram ; Belongs to the class of selective serotonin reuptake inhibitors. Used in the management of depression.
Presentation/Packing
Form
RiteMED Escitalopram FC tab 10 mg
Packing/Price
1 × 30's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in